Marco Beckmann, CEO of Nanostart
AG, the global nanotechnology investment company based in Frankfurt, will
be presenting the company and its portfolio holdings to an audience of approx.
80 selected investors and analysts on November 5 in New York City's Manhattan
The occasion for this special investor event is first and foremost the superb
results of clinical trials reported by MagForce Nanotechnologies AG (ISIN DE000A0HGQF5),
which is 77% owned by Nanostart. On November 3, MagForce announced the successful
completion of its clinical trials demonstrating the efficacy of its Nano-Cancer®
therapy in treating recurrent glioblastoma, a particularly malignant form of
brain tumor. The median survival time was more than doubled in the patient group,
far in excess of the study objective. These clinical trials thus conclusively
demonstrated the efficacy of Nano-Cancer® therapy. The study also confirmed
that the therapy is extremely well tolerated by patients compared to conventional
therapies, with no significant side effects.
The presentation will take place as part of an evening program. Marco Beckman
will be in the spotlight as the event's sole speaker, and guests will
have ample time following the formal presentation to speak individually with
him and to ask detailed questions.
Vanessa Mieschke, responsible for investor relations at Nanostart, commented:
“With these superb results from its clinical trials, our majority-owned
MagForce is entering into a new era. Large U.S. investors have been awaiting
these results with anxious anticipation.”